Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.healun.2021.04.003 http://scihub22266oqcxt.onion/10.1016/j.healun.2021.04.003 34034958!8058049!34034958     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Heart+Lung+Transplant 2021 ; 40 (8): 759-762 Nephropedia Template TP {{tp|p=34034958|t=2021. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response |pdf=|usr=}}{{34034958}} gab.com Text BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response JO: J Heart Lung Transplant http://www.kidney.de/pget.php?&tw=1&pmid=34034958 #FOAvip BACKGROUND: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse. METHODS: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies. RESULTS: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR?=?0.12, p?=?0.042). CONCLUSIONS: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown. Twit Text FOAVip BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response ????J Heart Lung Transplant http://www.kidney.de/pget.php?&tw=1&pmid=34034958 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34034958 #FOAvip English Wikipedia <ref>{{Cite pmid|34034958}}</ref> BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response #MMPMID34034958 Peled Y; Ram E; Lavee J; Sternik L; Segev A; Wieder-Finesod A; Mandelboim M; Indenbaum V; Levy I; Raanani E; Lustig Y; Rahav G J Heart Lung Transplant 2021[Aug]; 40 (8): 759-762 PMID34034958show ga BACKGROUND: Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse. METHODS: We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies. RESULTS: BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR?=?0.12, p?=?0.042). CONCLUSIONS: Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown. |*Heart Transplantation[MESH] |Aged[MESH] |Antibody Formation[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/adverse effects/*immunology[MESH] |COVID-19/*prevention & control[MESH] |Female[MESH] |Humans[MESH] |Immunosuppression Therapy[MESH] |Male[MESH] |Middle Aged[MESH] |Postoperative Complications/*prevention & control/*virology[MESH]BNT162b2 vaccination in heart transplant recipients: Clinical experien(epmc).pdf DeepDyve Pubget Overpricing